What Tecfidera Tells Us About the Size of the Nrf2 Medical and Supplementation Market
According to an article published by Foxnews entitled ” FDA approves new oral MS drug, Tecfidera” the following information reveals just how big the market is for NRF2 activating medications and supplements. Tecfidera has been FDA approved to treat just one disease, Multiple Sclerosis. From studies published on Pubmed.gov, NRF2 deficiencies is potentially tied to hundreds of additional diseases and illnesses. The statistics and market impact mentioned in this article is a “drop in the bucket” when it comes to the entire potential for the NRF2 activator industry.
size of nrf2 market

According to an article published by Foxnews entitled " FDA approves new oral MS drug, Tecfidera" the following information reveals just how big the market is for NRF2 activating medications and supplements. Tecfidera has been FDA approved to treat just one disease, Multiple Sclerosis. From studies published on Pubmed.gov, NRF2 deficiencies is potentially tied to hundreds of additional diseases and illnesses. The statistics and market impact mentioned in this article is a "drop in the bucket" when it comes to the entire potential for the NRF2 activator industry.

  • Biogen is expected to become the largest oral treatment for MS with annual sales exceeding $3-Billion within the next 5 years according to data compiled by Thomson Reuters Cortellis
  • Multiple sclerosis affects more than 2.1 million people globally
  • The share price of Biogen, producer of Tecfidera have tripled over the past three years upon the hope that this drug would be a big money producer for the company
  • There is a huge demand for oral based medication compared to the injected alternatives
  • European and US approval of Tecfidera has significantly increased the odds of Biogen meeting its revenue goals
  • According to Businessweek, "Biogen Idec Inc. (Nasdaq: BIIB) charges $54,900 a year for Tecfidera, its new and promising treatment for multiple sclerosis, and a rival of Teva Pharmaceutical Industries' (NYSE: TEVA; TASE: TEVA) Copaxone. The US Food and Drug Administration (FDA) approved Tecfidera for sale last week, and analysts believe that it will become the market leader within a few years."

Sign Up for Our Newsletter



Read More

Oxidative Stress
New Protandim Study – International Formula Impact on Oxidative Stress
There are numerous studies about the USA Protandim formula. This one is about the International formulation.
Augusta Nrf2 Study
Augusta University Discovers How Nrf2 Activator Preserves Sight in Retinal Degeneration Model
“We are very, very pleased that we can now explore the mechanisms,”, mentioned Dr. Sylvia Smith, chair of the Department of Cellular Biology and Anatomy at the Medical College of Georgia at Augusta University and co-director of the James and Jean Culver Vision Discovery Institute at AU.
persistent fibrosis
Reversal of persistent fibrosis in aging by targeting nox4-Nrf2 redox imbalance – Sciencemag.org
This is a promising study because the current treatments of pathological and cystic fibrosis are costly and very time consuming. Persistent fibrosis in lungs of aged mice was caused by the loss of cellular redox balance. The mice in the study with low NRF2 expression had a higher incidence of progressive lung disease. Tissues from human lung samples demonstrated this same Nox4-Nrf2 imbalance.

Next Steps

Get Our Free Newsletter

View Resources

Take Our Quiz

0

PROJECTS COMPLETED

0

ACTIVE CLIENTS

0

CUPS OF COFFEE

0

HAPPY CLIENTS

TESTIMONIALS

What They Say?

SEND US YOUR FEEDBACK

Get a face-to-face appoinment with our qualified specialists

PHONE NUMBER

+ 924 888 0250

EMAIL ADDRESS

hello@spirit.health

OUR LOCATION

Crown Rd. 14b, San Diego, California


© 2021 / Spirit Health / All rights reserved

Malcare WordPress Security